Loading…

Veeva SystemsVEEVCompetitor analysis, valuation and peers

United States · USD·Health Care›Packaged Software

US cloud software company selling industry-specific applications for life sciences (pharma/biotech) companies.

Momentum leader 91
Mkt cap
$44.9B
US dollars, full cap
Free float
91%
of shares outstanding
$/day
$428M
20-day average traded
Fwd P/E
28.7×
forward earnings
ROIC−WACC
n/a
WACC 9.5%
Hurdle
+6 pp
Req g minus delivered
Next earnings
15 days
3 Dec 2026
Close · USD$277.20
1D-3.9%
1W-9.1%
1M-13.0%
3M+10.7%
6M+68.0%
YTD+24.2%
1Y+0.1%
ATR %3.4%
Beta0.58
52w lowhigh15.0% off high

What Veeva Systems does

US cloud software company selling industry-specific applications for life sciences (pharma/biotech) companies.

Sells annual subscriptions priced by user or module to drugmakers, who tend to stay for many years because the software holds validated regulatory records. Its newer Vault CRM is replacing the original CRM that ran on Salesforce's platform, so Veeva is moving to its own technology.

Products and services

  • Veeva CRM (commercial)
  • Vault (clinical/regulatory/quality)
  • Veeva Crossix (data/analytics)

Customers

  • Pharmaceutical companies
  • Biotech/medical device companies

Where it sits in the supply chain

  • Software (vertical SaaS)
  • Life sciences CRM & clinical/regulatory…
  • Pharma, biotech, medical device…

What could go right

  • Vault platform cross-sell to existing pharma base
  • New biotech/emerging pharma customer growth

What could go wrong

  • Salesforce platform-dependency transition risk
  • Life sciences customer budget cyclicality

Moat: wide (switching costs, regulatory licence, installed base). Deep integration into regulated pharma workflows and validation requirements make switching costly and risky.

Headquarters: Pleasanton, California, US · Founded: 2007 · Employees: 7,928

Named competitors

Veeva Systems at a glance

Size Veeva Systems (VEEV) is a United States Health Care company (Packaged Software) with a market value of $44.9B, the 275th largest of 3,085 United States companies the cockpit tracks. Shares closed at $277.20 on 18 Nov 2026.

Performance Over six months the shares gained 68.0%, against +27.0% for the median peer and -2.2% for the United States market (cap-weighted) — highest of 21 in its peer set.

Growth Revenue grew 16.5% over the last twelve months (peer median +9.0%); the operating margin is 29.9% (peer median 18.4%).

Valuation It trades at 28.7× forward earnings against a peer median of 19.2× (6th most expensive of 19).

Price implies For today's price to make sense, revenue must grow about 23% a year for seven years (Req g). Recent delivered growth is +17%, so the hurdle is +6 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Short interest Short interest is 2.4% of the free float (30 Oct 2026).

Next results Next results expected around 3 Dec 2026 (exchange calendar; dates can move).

Relative performance

10015020021 May 202621 Aug 202618 Nov 2026VEEV 175Peer median 127
Six months, rebased to 100: Veeva Systems against the median of its 20 peers (local-currency closes).

Veeva Systems financials

Reported figures in USD; fiscal year ends 2026-01-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$3.46B$3.20B$2.75B$2.36B$2.16B
Revenue growth—+16%+16%+10%—
Gross profit$2.59B$2.40B$2.03B$1.67B$1.53B
EBITDA$1.09B$997M$747M$466M$497M
Net income$1.01B$909M$714M$526M$488M
Free cash flow$1.64B$1.39B$1.07B$885M$767M
Capital expenditure$26.7M$29.1M$20.5M$26.2M$13.5M
Total debt$152M$95.9M$75.8M$55.8M$61.0M

Quarterly statements and history in the cockpit →

Veeva Systems competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

+20%+40%+60%-20%0%+20%WATHUMIQVNTRATEVAARPRXMDLNGEHCBIIBIDXXZTSRVMDMTDBDXRMDARGXCNCEWBSXVEEV6-month return →1-month return →
Up and to the right = strong over both horizons. Veeva Systems is the large dot.

Fundamentals: revenue growth against valuation

0%+25%+50%+75%10×20×30×40×WATHUMIQVTEVAARPRXMDLNGEHCBIIBIDXXZTSMTDBDXARGXCNCEWBSXVEEVRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Veeva Systems is the large dot.

Capital: growth delivered against growth the price implies

0%+50%+100%+150%0%50%100%150%WATHUMIQVTEVAAZTSARGXVEEVGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Veeva Systems is the large dot.

Veeva Systems competitors and peer comparison

Head to head with its named competitors (VEEV vs CRM vs IQV vs ORCL)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Veeva Systems VEEV$44.9B+68%+16%30%28.7×23.1%
Salesforce CRM$157B+6%+11%22%13.0×12.0%
Iqvia IQV$42.5B+50%+9%14%18.7×16.8%
Oracle ORCL$344B-39%+22%34%13.3×n/a

How Veeva Systems compares with its peers

Peer set: Sector in the same market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Veeva Systems against its 20 peers (data as of 18 Nov 2026)
MeasureVEEVPeer medianRank in peer set
1-month return-13.0%+4.3%3rd lowest of 21
6-month return+68.0%+27.0%highest of 21
Distance from 52-week high-15.0%-9.3%7th lowest of 21
Revenue growth (TTM)+16.5%+9.0%5th highest of 20
Operating margin29.9%18.4%5th highest of 21
Forward P/E28.7×19.2×6th most expensive of 19
Growth the price implies (Req g, 7 yrs)23.1%10.6%4th most demanding of 19
Growth delivered (Del g)+16.9%+7.0%2nd highest of 19
Hurdle (Req g minus delivered)+6.2 pp+7.3 pp10th least demanding of 19
EV / EBITDA34.7×19.7×3rd most expensive of 17
Net debt / EBITDA-6.5×2.0×least indebted of 17

Peer table

Peer set: Sector in the same market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Veeva Systems VEEVUnited States$44.9B+68%+16%30%28.7×23.1%+16.9%
Waters WATUnited States$45.8B+37%+81%10%29.1×48.1%+6.0%
Humana HUMUnited States$46.3B+27%+22%2%22.1×5.5%+10.9%
Iqvia IQVUnited States$42.5B+50%+9%14%18.7×16.8%+7.5%
Natera NTRAUnited States$42.0B+41%+37%-9%n/an/an/a
Teva Pharmaceutical Industries Limited Sponsored ADR TEVAUnited States$49.3B+23%-4%19%15.0×10.5%+1.0%
Agilent Technologies AUnited States$50.0B+56%+9%24%27.0×23.3%+5.4%
Royalty Pharma RPRXUnited States$39.4B+29%+11%66%11.5×10.8%+2.3%
Medline MDLNUnited States$51.5B+8%+12%6%25.6×15.9%+9.9%
GE HealthCare GEHCUnited States$37.8B+30%+7%14%15.6×5.0%+3.7%
Biogen BIIBUnited States$37.2B+34%+2%17%17.1×10.1%-5.1%
Idexx Laboratories IDXXUnited States$55.0B+26%+12%32%42.9×29.0%+9.7%
Zoetis ZTSUnited States$34.8B+7%+1%37%13.8×-2.9%+7.2%
Revolution Medicines RVMDUnited States$34.6B+6%n/a-853%n/an/an/a
Mettler Toledo MTDUnited States$34.6B+60%+7%29%33.7×20.1%+5.5%
Becton Dickinson BDXUnited States$58.9B+48%-7%16%16.3×-1.6%+0.3%
ResMed RMDUnited States$34.1B+16%+9%34%19.7×5.7%+12.1%
argenx SE Sponsored ADR ARGXUnited States$59.1B+17%+71%29%29.0×11.7%+151.4%
Centene CNCUnited States$33.4B+16%+10%1%12.8×1.0%+11.9%
Edwards Lifesciences EWUnited States$60.5B+27%+13%29%32.3×17.1%+6.7%
Boston Scientific BSXUnited States$63.3B-23%+9%21%14.1×5.8%+15.2%

Questions

Who are Veeva Systems's main competitors?
Named competitors: Salesforce (Life Sciences Cloud) (CRM), IQVIA (IQV), Oracle Health Sciences (ORCL), Medidata (Dassault) (private or unlisted). The cockpit's measured peer set (sector in the same market, nearest in size) also includes Waters (WAT), Humana (HUM), Iqvia (IQV), Natera (NTRA), Teva Pharmaceutical Industries Limited Sponsored ADR (TEVA), Agilent Technologies (A).
Is Veeva Systems expensive compared with its peers?
On forward p/e it trades at 28.7× against a peer median of 19.2×, 6th most expensive of 19 in its peer set. For today's price to make sense, revenue must grow about 23% a year for seven years (Req g). Recent delivered growth is +17%, so the hurdle is +6 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has Veeva Systems stock performed?
Over six months to 18 Nov 2026 the shares returned +68.0% against +27.0% for the median peer; over one year +0.1%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.